The Centers for Medicare & Medicaid Services (CMS) on Monday proposed a significant change to how it covers a common heart valve procedure. The agency wants to drop the requirement that patients with symptomatic severe aortic stenosis must be part of a clinical study to qualify for coverage of Transcatheter Aortic Valve Replacement, or TAVR.

For those who don't speak medical jargon, aortic stenosis is basically a narrowing of the heart's aortic valve that restricts blood flow. TAVR is a less invasive way to replace that valve, and it's been a huge growth driver for Edwards Lifesciences (EW).

William Blair analyst Brandon Vazquez called the proposal a win for Edwards, saying it "largely validates the thesis we laid out following the NCD opening in December." The firm maintains an Outperform rating on the stock.

What's Changing

Beyond dropping the evidence-development requirement for symptomatic patients, CMS also proposed expanding TAVR coverage to patients with asymptomatic severe aortic stenosis—but under the evidence-development framework. That means patients who don't yet have symptoms could get the procedure, as long as their data is collected for further study.

The agency also wants to update criteria for pre-procedure evaluations, intraoperative standards, and volume requirements for operators and hospitals. In plain English: more patients could get the procedure, and the rules around who can perform it would be clearer.

Why Edwards Wins

Here's the key detail: Edwards currently has the only FDA-approved TAVR device indicated for asymptomatic severe aortic stenosis patients. That approval came in April 2025, when the FDA expanded the label for Edwards' SAPIEN 3 valve based on the EARLY TAVR trial data.

If CMS finalizes the coverage expansion for asymptomatic patients, Edwards would have a "meaningful competitive advantage," according to William Blair. Rivals would need to get their own FDA approvals for that population before they could benefit from the broader coverage.

Vazquez noted that coverage with evidence development makes sense for asymptomatic patients, since they represent an earlier-stage treatment population. Continued data collection should benefit everyone—patients, doctors, and device makers alike.

The Bigger Picture

Simplifying the coverage pathway could accelerate TAVR adoption overall. When patients and doctors don't have to navigate complex clinical trial requirements, more people are likely to get the procedure sooner. That's good for patients, and it's good for Edwards.

Shares of Edwards Lifesciences were up 3.74% at $88.65 on Tuesday afternoon, reflecting investor optimism about the proposal.

The CMS proposal is open for public comment before a final decision. But for now, Edwards looks like the clear winner in this regulatory shift.